Abstract:
Despite the hardships of major depressive disorder (MDD), biomarkers for the diagnosis and pharmacological management of this condition are lacking. MicroRNAs are epigenetic mechanisms that could provide promising MDD biomarkers. Our aim was to summarize the findings and provide validation for the selection and use of specific microRNAs as biomarkers in the diagnosis and treatment of MDD. A systematic review was conducted using the PubMed/Medline, Cochrane, PsycINFO, Embase, and LILACS databases from March 2022 to November 2023, with clusters of terms based on \"microRNA\" and \"antidepressant\". Studies involving human subjects, animal models, and cell cultures were included, whereas those that evaluated herbal medicines, non-pharmacological therapies, or epigenetic mechanisms other than miRNA were excluded. The review revealed differences in the expression of various microRNAs when considering the time of assessment (before or after antidepressant treatment) and the population studied. However, due to the heterogeneity of the microRNAs investigated, the limited size of the samples, and the wide variety of antidepressants used, few conclusions could be made. Despite the observed heterogeneity, the following microRNAs were determined to be important factors in MDD and the antidepressant response: mir-1202, mir-135, mir-124, and mir-16. The findings indicate the potential for the use of microRNAs as biomarkers for the diagnosis and treatment of MDD; however, more homogeneous studies are needed.
摘要:
尽管重度抑郁症(MDD)的困难,缺乏用于诊断和治疗这种疾病的生物标志物。MicroRNAs是表观遗传机制,可以提供有前途的MDD生物标志物。我们的目的是总结这些发现,并为在MDD的诊断和治疗中选择和使用特定的microRNA作为生物标志物提供验证。使用PubMed/Medline进行了系统评价,科克伦,PsycINFO,Embase,和LILACS数据库,从2022年3月到2023年11月,其术语集群基于“microRNA”和“抗抑郁药”。涉及人类受试者的研究,动物模型,包括细胞培养物,而那些评估草药的人,非药物疗法,或miRNA以外的表观遗传机制被排除。该综述揭示了在考虑评估时间(抗抑郁药治疗之前或之后)和所研究人群时,各种microRNAs表达的差异。然而,由于所研究的microRNAs的异质性,样品的尺寸有限,使用的抗抑郁药种类繁多,可以得出的结论很少。尽管观察到了异质性,以下microRNA被确定为MDD和抗抑郁反应的重要因子:mir-1202,mir-135,mir-124和mir-16.研究结果表明,使用microRNAs作为诊断和治疗MDD的生物标志物的潜力;然而,需要更多的同质研究。